Global Health Ventures to Initiate Prototype Manufacturing of a Sublingual Anti-Anxiety Drug Through Agreement With Carter Pharmaceutical Consulting Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 29, 2010) - Global Health Ventures Inc. (OTCBB: GHLV) (the "Company"), a specialty pharmaceutical company today announced that it has signed an agreement with Carter Pharmaceutical of Toronto, Canada, to manufacture the prototype of its anti-anxiety drug "Relax-B". Together, the companies will manufacture about 10,000 pills for carrying out the necessary testing of the product prior to the initiation of a bioequivalent study in man. The Company plans to carry out the clinical trials of this product in North America under the FDA guideline. This study with Carter Pharmaceuticals is expected to take about two to three months.

"We are pleased to announce that we will initiate the clinical trials for our second drug Relax-B in North America under the FDA guideline. Our first drug X-Excite which is designed for the male sexual enhancement is going through similar studies in Europe. We plan to get some drugs in developmental stages approved in Europe first and then in United States, while some drugs in United States first and then in Europe", said Dr. Hassan Salari, President and CEO.

About Relax-B

Relax-B is a sublingual formulation of an already FDA approved drug. The current formulation is used by more than 10 million patients worldwide generating billions of dollars for large pharmaceutical companies. Our formulation that uses our proprietary sublingual technology allows a new market for this drug and is expected to have similar market potential. Anxiety and nervousness is one of the major problems with many people in western countries and we believe that our product can capture enormous market worldwide.

ABOUT GLOBAL HEALTH VENTURES - Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy, heart medication and addiction replacement.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.